Altimmune Plunges 61.35% Ahead of MASH Trial Readout

On June 26, 2025, Altimmune's stock experienced a significant drop of 61.35% in pre-market trading, marking a dramatic shift in investor sentiment.

Altimmune's recent stock performance can be attributed to the upcoming readout of its MASH trial, which has been a focal point for investors. The company's stock had previously surged in anticipation of the trial results, reflecting high expectations for the outcome. However, the recent drop suggests that investors may be reassessing their positions ahead of the official announcement.

Altimmune is set to host an investor webcast to present the topline data from its IMPACT Phase 2b trial of Pemvidutide for the treatment of MASH. This trial is crucial for the company as it aims to demonstrate the efficacy of its drug candidate in treating this condition. The results from this trial will likely influence future investment decisions and the company's strategic direction.

Altimmune's stock movements highlight the volatility and uncertainty that often accompany clinical trial readouts in the biotech sector. Investors are closely monitoring the company's progress, and the upcoming data release will be a key determinant of its future trajectory. The market's reaction to the trial results will provide further insights into the potential of Pemvidutide and Altimmune's overall prospects.